Early-stage financing paves the path to success for an innovative asset. Grant financing is a lower-risk option, maintaining the company’s independence in the first steps of its development. The EU is an instrumental source of non-dilutive funding for innovative MedTech companies. It recently issued the new Innovative Health Initiative (IHI) to foster innovation through public-private partnership between the European Union and MedTech industry companies. How can a company benefit from this program? How to build a successful European funding strategy? What are the other available grant options in Europe and how to benefit from them?
Moderator: Jeroen Schuermans, Senior Grant Consultant Life Sciences, Akkodis 
